EA201000002A1 - Полипептид апф2 - Google Patents

Полипептид апф2

Info

Publication number
EA201000002A1
EA201000002A1 EA201000002A EA201000002A EA201000002A1 EA 201000002 A1 EA201000002 A1 EA 201000002A1 EA 201000002 A EA201000002 A EA 201000002A EA 201000002 A EA201000002 A EA 201000002A EA 201000002 A1 EA201000002 A1 EA 201000002A1
Authority
EA
Eurasian Patent Office
Prior art keywords
apf2
polypeptid
acp2
dimer
polypeptide
Prior art date
Application number
EA201000002A
Other languages
English (en)
Other versions
EA027399B1 (ru
Inventor
Манфред Шустер
Ханс Лойбнер
Эвелин Янцек-Хавлат
Бернхард Пебаль
Штефан Штраннер
Беттина Вагнер
Роберт Вайк
Original Assignee
Апейрон Биолоджикс Форшунгс-Унд Энтвиклунгсгезельшафт М.Б.Х.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08450052A external-priority patent/EP2108695A1/de
Application filed by Апейрон Биолоджикс Форшунгс-Унд Энтвиклунгсгезельшафт М.Б.Х. filed Critical Апейрон Биолоджикс Форшунгс-Унд Энтвиклунгсгезельшафт М.Б.Х.
Publication of EA201000002A1 publication Critical patent/EA201000002A1/ru
Publication of EA027399B1 publication Critical patent/EA027399B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к рекомбинантному полипептиду АПФ2, где полипептид АПФ2 является димером. Димер специфически формируется из гликозилированных мономеров и используется для получения фармацевтических продуктов с продолжительным периодом полужизни.
EA201000002A 2007-06-12 2008-06-12 Рекомбинантный, гликозилированный, растворимый, димерный, ферментативно активный полипептид апф2 человека и его применение EA027399B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0091307A AT505262A1 (de) 2007-06-12 2007-06-12 Rekombinantes ace2 polypeptid
EP08450052A EP2108695A1 (de) 2008-04-08 2008-04-08 Ace2 Polypeptid
PCT/AT2008/000211 WO2008151347A1 (de) 2007-06-12 2008-06-12 Ace2 polypeptid

Publications (2)

Publication Number Publication Date
EA201000002A1 true EA201000002A1 (ru) 2010-08-30
EA027399B1 EA027399B1 (ru) 2017-07-31

Family

ID=39720296

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000002A EA027399B1 (ru) 2007-06-12 2008-06-12 Рекомбинантный, гликозилированный, растворимый, димерный, ферментативно активный полипептид апф2 человека и его применение

Country Status (35)

Country Link
US (3) US8586319B2 (ru)
EP (3) EP2543724B1 (ru)
JP (1) JP5731193B2 (ru)
KR (2) KR101682240B1 (ru)
CN (2) CN104450654A (ru)
AT (1) AT505262A1 (ru)
AU (1) AU2008261591B2 (ru)
BR (1) BRPI0813942B8 (ru)
CA (1) CA2692854C (ru)
CO (1) CO6270265A2 (ru)
CR (1) CR11213A (ru)
CY (2) CY1116873T1 (ru)
DK (2) DK2543724T3 (ru)
DO (1) DOP2009000282A (ru)
EA (1) EA027399B1 (ru)
EG (1) EG27095A (ru)
ES (2) ES2550390T3 (ru)
HK (2) HK1255493A1 (ru)
HR (2) HRP20151120T1 (ru)
HU (2) HUE037877T2 (ru)
IL (1) IL202653B (ru)
LT (1) LT2543724T (ru)
MA (1) MA31472B1 (ru)
MX (1) MX2009013472A (ru)
MY (1) MY180672A (ru)
NO (1) NO2543724T3 (ru)
NZ (1) NZ581704A (ru)
PL (2) PL2543724T3 (ru)
PT (2) PT2155871E (ru)
RS (2) RS57292B1 (ru)
SI (2) SI2543724T1 (ru)
TR (1) TR201808117T4 (ru)
UA (1) UA106869C2 (ru)
WO (1) WO2008151347A1 (ru)
ZA (1) ZA200908751B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
EP2077119A1 (de) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
AT506632A1 (de) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
JP2015520128A (ja) 2012-04-19 2015-07-16 オプコ バイオロジクス リミテッド 長時間作用性オキシントモジュリン変異体とその作製方法
ES2633894T3 (es) 2012-08-02 2017-09-25 F. Hoffmann-La Roche Ag Procedimiento para producir moléculas monoméricas y multiméricas y usos de las mismas
KR102202255B1 (ko) 2012-11-20 2021-01-13 옵코 바이오로직스 리미티드 생식샘자극 호르몬 카복시 말단 펩타이드들과 부착하여 폴리펩타이드들의 유체역학적 부피를 증가시키는 방법
US9757433B2 (en) 2013-01-14 2017-09-12 Apeiron Biologicals AG Modified ACE2 polypeptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
US10960058B2 (en) 2015-06-19 2021-03-30 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CN118085104A (zh) 2016-07-11 2024-05-28 Opko生物科学有限公司 长效凝血因子及其制备方法
US11518788B2 (en) * 2020-07-10 2022-12-06 Avirus, Inc. Methods and compositions for treating and preventing viral infection
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
EP3884957A1 (en) 2020-03-26 2021-09-29 The University of British Columbia Methods for treatment of virus and methods for screening of anti-virus reagent using organoids
US20230174611A1 (en) * 2020-04-24 2023-06-08 Administrators Of The Tulane Educational Fund Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor
CN113667016A (zh) * 2020-05-15 2021-11-19 普米斯生物技术(珠海)有限公司 一种构建冠状病毒抗体的平台
WO2021247675A1 (en) 2020-06-02 2021-12-09 Ngm Biopharmaceuticals, Inc. Coronavirus-binding agents and uses thereof
DE102020207224A1 (de) 2020-06-09 2021-12-09 Christoph Karle Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon
JP2023531368A (ja) * 2020-06-25 2023-07-24 グリックニック インコーポレイテッド Ａｃｅ２－ｆｃ融合タンパク質および使用方法
WO2022008642A1 (en) 2020-07-08 2022-01-13 Apeiron Biologics Ag Treatment of sars-cov-2 infection with a combination of targets
MX2023000504A (es) * 2020-07-10 2023-04-14 Biomolecular Holdings Llc Anticuerpos tetrahedricos.
WO2022037699A1 (en) * 2020-08-21 2022-02-24 Westlake University Engineered ace2 oligomers and uses thereof
CN112280764A (zh) * 2020-11-18 2021-01-29 通用生物系统（安徽）有限公司 一种新冠重组ace2蛋白在哺乳动物细胞中的生产方法
EP4011387A1 (en) 2020-12-11 2022-06-15 IMBA-Institut für Molekulare Biotechnologie GmbH Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2
WO2022159433A1 (en) 2021-01-20 2022-07-28 Singh Biotechnology, Llc Therapeutics directed against coronavirus
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022207918A1 (en) 2021-04-02 2022-10-06 Apeiron Biologics Ag COVID-19 Therapy
EP4387732A1 (en) 2021-08-19 2024-06-26 Phenom Pharmaceuticals, inc. Compositions and methods for treatment of sars cov-2
CN113897346A (zh) * 2021-09-16 2022-01-07 四川大学 能够提高与SARS-CoV-2 S蛋白亲和力的ACE2突变组合及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
SI1515752T1 (sl) * 2002-06-19 2009-06-30 Univ Health Network Aktivacija ACE2 za zdravljenje srčne, pljučne in ledvične bolezni in hipertenzije
AU2003276877A1 (en) 2002-09-09 2004-03-29 Millenium Pharmaceuticals, Inc. Crystal structure of angiotensin-converting enzyme-related carboxypeptidase
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
AT504443B1 (de) 2006-10-19 2008-11-15 Apeiron Biolog Forschungs Und Verfahren zur bestimmung der aktivität von ace2
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
EP2108695A1 (de) 2008-04-08 2009-10-14 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Ace2 Polypeptid
AT506258A1 (de) * 2007-12-18 2009-07-15 Apeiron Biolog Forschungs Und Behandlung inflammatorischer krankheiten
AT506632A1 (de) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen

Also Published As

Publication number Publication date
US8586319B2 (en) 2013-11-19
TR201808117T4 (tr) 2018-07-23
AU2008261591B2 (en) 2014-08-07
IL202653A0 (en) 2011-08-01
CA2692854A1 (en) 2008-12-18
PT2543724T (pt) 2018-06-11
EP2543724B1 (de) 2018-03-21
US10716833B2 (en) 2020-07-21
DK2543724T3 (en) 2018-05-28
BRPI0813942A2 (pt) 2014-12-30
RS57292B1 (sr) 2018-08-31
CY1120426T1 (el) 2019-07-10
EP2543724A3 (de) 2013-02-20
JP2011519264A (ja) 2011-07-07
ES2670938T3 (es) 2018-06-04
EA027399B1 (ru) 2017-07-31
WO2008151347A1 (de) 2008-12-18
PT2155871E (pt) 2015-10-26
BRPI0813942B1 (pt) 2019-08-20
CN104450654A (zh) 2015-03-25
MY180672A (en) 2020-12-05
DK2155871T3 (en) 2015-11-09
JP5731193B2 (ja) 2015-06-10
HRP20151120T1 (en) 2015-11-20
HUE028012T2 (en) 2016-11-28
ES2550390T3 (es) 2015-11-06
SI2543724T1 (en) 2018-07-31
LT2543724T (lt) 2018-06-25
US20180289779A1 (en) 2018-10-11
ZA200908751B (en) 2010-07-28
KR101682240B1 (ko) 2016-12-06
CA2692854C (en) 2017-07-04
US20140099297A1 (en) 2014-04-10
EP3375872A1 (de) 2018-09-19
KR20100040809A (ko) 2010-04-21
PL2155871T3 (pl) 2015-12-31
MX2009013472A (es) 2010-06-25
EP2543724A2 (de) 2013-01-09
NO2543724T3 (ru) 2018-08-18
CY1116873T1 (el) 2017-04-05
NZ581704A (en) 2012-05-25
RS54340B1 (en) 2016-02-29
BRPI0813942B8 (pt) 2021-05-25
KR20160054045A (ko) 2016-05-13
EG27095A (en) 2015-05-28
PL2543724T3 (pl) 2018-08-31
UA106869C2 (uk) 2014-10-27
US20100310546A1 (en) 2010-12-09
AT505262A1 (de) 2008-12-15
SI2155871T1 (sl) 2015-11-30
CR11213A (es) 2010-04-20
HRP20180856T1 (hr) 2018-08-24
EP2155871A1 (de) 2010-02-24
HUE037877T2 (hu) 2018-09-28
AU2008261591A1 (en) 2008-12-18
HK1136602A1 (en) 2010-07-02
CO6270265A2 (es) 2011-04-20
EP2155871B1 (de) 2015-08-12
MA31472B1 (fr) 2010-06-01
CN101796183A (zh) 2010-08-04
HK1255493A1 (zh) 2019-08-16
IL202653B (en) 2018-01-31
DOP2009000282A (es) 2010-03-31

Similar Documents

Publication Publication Date Title
EA201000002A1 (ru) Полипептид апф2
EP4269441A3 (en) Il-15 and il-15ralpha sushi domain based on modulokines
MX2013015393A (es) Inmunocitosinas basadas en un dominio sushi de il-15 y de il-15ra.
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
WO2013184938A3 (en) Fusion polypeptides comprising mucin-domain polypeptide linkers
NO20071419L (no) Polypeptidvarianter med endret effektorfunksjon
WO2006131564A3 (de) Neue cystein-verarmte hydrophobinfusionsproteine, deren herstellung und verwendung
EA200801460A1 (ru) Рекомбинантные моновалентные антитела и способы их получения
MX2017013892A (es) Inhibidores novedosos del factor xii activado por la enzima (fxiia).
ATE428731T1 (de) Therapeutische antiköper mit reduzierten nebenwirkungen
NZ607069A (en) Modified relaxin polypeptides and their uses
RS53455B (en) OPTIONS DERIVED FROM ActRIIB AND THEIR USE
DE602005008996D1 (de) Radiofluorierte peptide
EA201070739A1 (ru) Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и связанные с ними способы
UA118167C2 (uk) Пептид та його застосування
WO2010034718A8 (fr) Proteines recombinantes a activite hemostatique capables d'induire l'agregation plaquettaire
ATE551048T1 (de) Proteinhydrolysate enthaltende kosmetische zusammensetzungen
DE602006020032D1 (de) Il-21-varianten
ATE405654T1 (de) Polypeptid mit verbesserter cytosin-deaminase- aktivität
EA200800535A1 (ru) Пептиды и соединения, которые связываются с рецептором
ATE485379T1 (de) Zytotoxische ribonukleasevarianten
WO2014003538A8 (en) Rapid specific pathogen free animal
EA200801294A1 (ru) Пептиды-индукторы бактериоцина
NZ596501A (en) Casb7439 constructs
WO2009131698A3 (en) PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF